Axofen Tablet, Oral Suspension, Suspension

Axofen Hydrochloride is an antihistamine with selective peripheral H1 receptor antagonist activity. It inhibits histamine release from peritoneal mast cells. No anticholinergic, α-1 adrenergic or β-adrenergic receptor blocking effects has been observed. No sedative or other central nervous system effect has been observed. It does not appear to cross the blood brain barrier. 

Axofen is rapidly absorbed after oral administration with peak plasma concentration being reached in 2-3 hours. Elimination half-life of about 14 hours has been reported although this may be prolonged in patients with renal impairment.


It is used for the relief of symptoms associated with seasonal and perennial allergic rhinitis and chronic idiopathic urticaria.

Axofen is also used to associated treatment for these conditions: Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Seasonal Allergic Rhinitis, Antihistamine

Trade Name Axofen
Generic Fexofenadine
Other Names Carboxyterfenadine, Fexofenadina, Fexofenadine, Terfenadine acid metabolite, Terfenadine carboxylate, Terfenadine-COOH
Weight 120mg, 180mg, 30mg/5ml, 60mg, 100mg/5ml
Type Tablet, Oral Suspension, Suspension
Formula C32H39NO4
Weight Average: 501.6564
Monoisotopic: 501.287908741
Protein binding

Fexofenadine is 60-70% bound to plasma proteins, primarily to albumin and α1-acid glycoprotein. The extent of protein binding is decreased to 56-68% and 56-75% in patients with renal and hepatic impairment, respectively.

Therapeutic Class Non-sedating antihistamines
Manufacturer Aristopharma Ltd, Sampharindo Indonesia
Available Country Bangladesh, Indonesia
Last Updated: June 23, 2021 at 11:20 am


Axofen dosage


  • Allergic rhinitis: 120 mg once daily or 60 mg twice daily
  • Urticaria: 180 mg once daily


  • 2-11 years: 30 mg (1 spoonful) or 5 ml twice daily
  • 6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily

In case of decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.

Side Effects

Axofen is generally well tolerated. The most commonly reported adverse events are headache, drowsiness, nausea, and dizziness. The incidence of these events observed with Axofen hydrochloride was similar to that observed with placebo.


Studies in the elderly, patients with hepatic impairment and patients with cardiac disease exposed to Axofen showed no statistically significant differences compared to healthy individuals. As with most new drugs there is only limited data in the elderly and renally or hepatically impaired patients. Axofen hydrochloride should be administered with care in these special groups.


Co-administration of Axofen Hydrochloride with either ketoconazole or erythromycin may cause increased plasma concentration of Axofen. Antacid containing Aluminium and Magnesium may reduce the absorption of Axofen. Fruit juices such as grapefruit, orange and apple may reduce the bioavailability of Axofen.

Food Interaction

  • Avoid fruit juice. Fruit juices like grapefruit, orange, and apple may reduce bioavailability and overall exposure to the medication.
  • Take with or without food. Co-administration with food does not significantly affect absorption.

Volume of Distribution

The volume of distribution is approximately 5.4-5.8 L/kg.

Half Life

The terminal elimination half-life is approximately 11-15 hours.


The oral clearance of fexofenadine is approximately 50.6 L/h and the renal clearance is approximately 4.32 L/h.

Pregnancy & Breastfeeding use

Pregnancy Category B. There are no adequate and well controlled studies in pregnant women. Axofen should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation: It is not known if Axofen is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Axofen is administered to a nursing woman.


Axofen is contraindicated in patients with known hypersensitivity to Axofen or any of the ingredients of Axofen Hydrochloride.

Special Warning

Studies in special risk groups (elderly, renally or hepatically impaired patients) indicate that it is not necessary to adjust the dose of Axofen Hydrochloride in these patients.

Acute Overdose

In case of an overdose, standard measures to remove any unabsorbed drug should be employed. Symptomatic and supportive treatment is recommended. There has been no reported case of an acute overdose of Axofen hydrochloride.

Storage Condition

Store Axofen at controlled room temperature 20-25 °C. Keep all medicines away from reach of children.

Axofen contains Fexofenadine see full prescribing information from innovator Monograph